American College of Rheumatology

Mease discussed the latest updates on deucravacitinib and zasocitinib at ACR Convergence 2025.

Ramsey-Goldman discussed how the lupus field has shifted from her earlier career.

ACR 2025 research shows polygenic risk scores correlate with specific SLE phenotypes, highlighting potential applications for clinical risk assessment.

At ACR 2025, Dapas discusses how polygenic risk scores link genetic risk to SLICC criteria, advancing precision medicine in systemic lupus erythematosus.

Mease discussed the latest updates on apremilast and growing attention to cardiometabolic outcomes at ACR Convergence 2025.

Ramsey-Goldman emphasized the importance of QoL in lupus, looking beyond disease scores.

Ramsey-Goldman discussed the potential of NAC for treating systemic lupus erythematosus.

Khasru discussed the potential of adMSCs to improve outcomes in knee osteoarthritis.

Cuda also discussed further research she'd like to do with cognition and SLE.

Cuda discussed the potential of the NIH toolbox to easily assess cognitive effects in clinical trials.

Mease discussed the latest updates on bimekizumab, sonelokimab, and izokibep at ACR Convergence 2025.

Telitacicept significantly alleviates Sjögren disease symptoms over 48 weeks, outperforming placebo with a favorable safety profile in a phase 3 trial.

View slated expert interviews and 6 clinical RA, PsA, and lupus trials to watch at ACR 2025.

However, a notable higher rate of treatment-related adverse events warrants caution.

Sonelokimab meets ACR50 primary endpoint in a phase 2 trial.

In this data shown at ACR 2023, the URAT1 inhibitor known as AR882 showed promising phase 2b data for patients with gout.

In these phase 3 findings presented at ACR 2023, the safety and efficacy of this drug was proven in ACR20, ACR50, and DAS28-ESR responses.

In this late-breaking research shown at ACR 2023, TLC599 injection led to benefits in patients with a single injection and further benefits with a second.

This new late-breaking data presented at ACR 2023 was the first clinical evidence indicating efficacy of afimetoran for those with CLE.

New data presented at ACR 2023 highlighted the differences in rates of flares and Boolean 2.0 remission rates compared to patients with rheumatoid arthritis who continued TNFi.

In this research presented at ACR 2023, a connection between antiphospholipid antibodies and a greater potential risk of cardiovascular disease was identified.

This segment of Dr. Kivitz’s interview at ACR 2023 featured a discussion about future research on TAK-279 as well as general outlook on the field for psoriatic arthritis.

During this interview, Dr. Kivitz explained the background and key findings of his team’s research on TAK-279, a selective oral TYK2 inhibitor.

This data represented the first-ever research presented at ACR on both fractures and calcium pyrophosphate deposition disease.

This segment of Dr. Fakih’s interview featured a discussion on the implications of his team’s findings presented at ACR 2023.

This interview segment with Dr. Fakih featured a discussion about his team’s findings and their methodology on the topic of spondyloarthritis.

In this discussion with Dr. Hunter, the findings his team presented at ACR 2023 were explored, including a discussion about their implications for the future of osteoarthritis treatment.

This research into improving quality measures for lupus patients was presented at ACR 2023 and funded by the CDC.

This discussion with Dr. Hunter covered the takeaways from his team’s phase 3 findings on treatment of osteoarthritis of the knee.

During this interview segment, Dr. Alevizos discussed some of the implications of his team’s findings regarding dazodalibep.